5/8/2023 0 Comments Tetra bio pharma![]() Other than as disclosed herein, the Company is up to date in its filing obligations. The Company confirms other than its financial results for the year ended November 30, 2022, there is no other material information relating to its affairs that has not been generally disclosed. ![]() The Company confirms that it will satisfy the provisions of the alternative information guidelines under NP 12-203 by issuing biweekly default status reports in the form of news releases for so long as it remains in default of the above-noted filing requirements. The management cease trade order, if approved, will generally not affect the ability of persons who are not or have not been management of the Company to trade in its securities. The Company has applied to the Ontario Securities Commission, as principal regulator for the Company, for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203") throughout the duration of the default. ![]() The Company also announced PwC (PricewaterhouseCoopers LLP) has resigned as auditors and are now working with McGovern Hurley LLP to complete the preparation of these filings and expects to file its 2022 annual financial statements and related management's discussion and analysis on or before April 15, 2023. ("Tetra" or the "Company") (TSX: TBP) (OTC-PINK: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that it will not be in a position to file its audited annual financial statements for the year ended November 30, 2022, the related management's discussion and analysis and related CEO and CFO certificates before the required deadline of February 28, 2023. ![]() MONTREAL, QUEBEC – TheNewswire – Ma- Tetra Bio-Pharma Inc. ![]()
0 Comments
Leave a Reply. |